On Jan. 20, the U.S. Food and Drug Administration (FDA) announced that testing positive for anti-JC virus antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection associated with use of Tysabri (natalizumab) for the treatment of multiple sclerosis or Crohn’s disease. Read more.
FDA announces new risk factor for PML associated with Tysabri
Most Recent Content
For Nurse Practitioners
Quiz: Migraines and Hormones
Women are 2 to 3 times more likely than men to have migraines. Decades ago, these were attributed to women’s inability to cope with...
